Fulgent Genetics Inc Dossier
Qualitative Analysis
Business overview
Fulgent Genetics, Inc. (NASDAQ: FLGT) is a technology-based company that operates in two primary segments: laboratory services and therapeutic development. The laboratory services business provides comprehensive molecular diagnostic and genetic testing services, including next-generation sequencing (NGS), anatomic pathology, and oncology diagnostics. The therapeutic development business (Fulgent Pharma) focuses on developing novel nanoencapsulated drug candidates, such as FID-007 and FID-022, to improve the therapeutic window and pharmacokinetic profile of cancer treatments. The company is actively transitioning from a pure-play diagnostics provider into a fully integrated precision medicine company.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing clinical development of proprietary nano-encapsulated therapeutic candidates, specifically FID-007 (targeting head and neck squamous cell carcinoma) and FID-022 (targeting solid tumors).
Expected impact: Transforms Fulgent from a pure-play diagnostics laboratory into a fully integrated precision medicine company, opening up multi-billion dollar oncology market opportunities.
Deploying digital pathology workflows and artificial intelligence modules across laboratory services, utilizing Eziopath, a proprietary image management system (IMS).
Expected impact: Improves diagnostic efficiency, reduces per-unit costs, and enhances clinical workflow quality, driving operating leverage in the anatomic pathology segment.
Expanding the anatomic pathology and dermatopathology footprint to mitigate customer concentration risks, specifically following the loss of its largest customer in-housing its testing volume.
Expected impact: Expected to add $50.0 million to $55.0 million in offset revenue, reducing customer concentration so that no single customer represents more than 10% of 2026 revenue.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire premier pathology and dermatopathology laboratory assets, adding new anatomic pathology services, proprietary PCR tests, a national sales team, and a broad national client base.
Financial impact: Expected to contribute approximately $50.0 million to $55.0 million in revenue for fiscal year 2026, helping to offset the loss of Fulgent's largest customer.